TaiMed Biologics (ROCO:4147) GF Value Rank: 10 (As of Aug. 13, 2026) — 150% Above Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:4147 TaiMed Biologics Inc ROCO:4147
65 GF Score
Price NT$65.20
GF Value NT$80.94
Valuation Modestly Undervalued
View Full Analysis

What is TaiMed Biologics GF Value Rank?

TaiMed Biologics ROCO:4147 -4.82% 65 GF Value Rank is 10 as of Aug. 13, 2026, which is 150% above its 10-year median of 4.00. GuruFocus rates ROCO:4147 with a GF Score™ of 65/100 and a GF Value™ of NT$80.94 (Modestly Undervalued).

TaiMed Biologics has the GF Value Rank of 10.

GF Value Rank evaluates the exclusive GuruFocus valuation and performance of a stock, rated on a scale from 1 to 10. It is determined by the price-to-GF-Value (P/GF Value) ratio, a proprietary metric calculated based on historical multiples along with an adjustment factor based on a company's past returns and growth and future estimates of the business' performance.

GuruFocus found that for valuation, we cannot simply give stocks a better GF Value rank simply because they have a lower P/GF Value ratio. Backtesting shows that over the long term, the two worst-performing groups are the most expensive group (with the highest P/GF Value ratio) and the least expensive group (with the lowest P/GF Value ratio).

We can understand why the most expensive group underperforms. We were initially puzzled by the underperformance of the least expensive group, but we realized there is a reason why some stocks are super cheap. If they look too undervalued, it is often because the businesses behind them are poor quality. The market realized this and gave them low valuations. In a way, the market is efficient.

After multiple backtesting analyses, we granted the stocks in third-cheapest percentile the highest GF Value rank, as they have performed the best over a full market cycle. Stock performance is actually not as sensitive to valuation as it is to growth and profitability. On average, the companies in the 20%-50% valuation groups have similar performances. Therefore, we should avoid the most expensive and the least expensive stocks. We can be more tolerant of valuation.

A higher score indicates a stock with a relatively low valuation and substantial potential for outperformance. Conversely, a lower score often reflects stocks that are either highly overvalued or deeply undervalued, both of which tend to underperform.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.


TaiMed Biologics GF Value Rank Related Terms


ROCO:4147 vs VRTX, REGN, RVMD: GF Value Rank Comparison

For the Biotechnology subindustry, TaiMed Biologics's GF Value Rank, along with its competitors' market caps and GF Value Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


TaiMed Biologics GF Value Rank vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, TaiMed Biologics's GF Value Rank distribution charts can be found below:

* The bar in red indicates where TaiMed Biologics's GF Value Rank falls into.


ROCO:4147
65GF Score
TaiMed Biologics Inc ROCO:4147
GF Value Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about GF Value Rank →
What does a GF Value Rank of 10 mean?
TaiMed Biologics (ROCO:4147) has a GF Value Rank of 10 as of Aug. 13, 2026. GF Value Rank is given based on historical multiples along with past returns, growth and future estimates of the business' performance. View historical data on TaiMed Biologics and its competitors. This is 150% above median its historical median of 4.00. Over the past decade, TaiMed Biologics' GF Value Rank has ranged from 2.00 to 10.00.
Is TaiMed Biologics' GF Value Rank too high?
TaiMed Biologics' current GF Value Rank of 10 is 150% above median its 10-year median of 4.00. Over the past 10 years, this metric has ranged from a low of 2.00 to a high of 10.00. Overall, TaiMed Biologics has a GF Score™ of 65/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does TaiMed Biologics' GF Value Rank compare to VRTX and REGN?
TaiMed Biologics' GF Value Rank of 10 can be compared against companies in the Biotechnology industry. Historically, TaiMed Biologics' own GF Value Rank has ranged from 2.00 to 10.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good GF Value Rank for a Biotechnology company?
A good GF Value Rank depends on the Biotechnology industry context. However, GF Value Rank should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high GF Value Rank mean?
A high GF Value Rank can signal that a stock is expensive relative to its fundamentals. GF Value Rank is given based on historical multiples along with past returns, growth and future estimates of the business' performance. View historical data on TaiMed Biologics and its competitors. TaiMed Biologics's current GF Value Rank is 10, which is 150% above median its own 10-year median of 4.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TaiMed Biologics stock overvalued right now?
Based on GuruFocus' analysis, TaiMed Biologics (ROCO:4147) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$80.94, compared to a current price of NT$65.20 — trading 19.4% below its estimated fair value. The current GF Value Rank is 10, which is 150% above median its 10-year median of 4.00. TaiMed Biologics' overall GF Score™ is 65/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is GF Value Rank calculated?
GF Value Rank is calculated from a company's financial statements. For TaiMed Biologics (ROCO:4147), the current GF Value Rank is 10 as of Aug. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is TaiMed Biologics (ROCO:4147) Overvalued in 2026?

Based on GuruFocus' analysis, TaiMed Biologics stock appears to be undervalued. The current stock price of NT$65.20 is trading 19.4% below its estimated GF Value™ of NT$80.94. GuruFocus considers TaiMed Biologics to be Modestly Undervalued.

Key valuation signals for ROCO:4147:

  • GF Value Rank: 10 (150% above median its 10-year median of 4.00)
  • GF Value™: NT$80.94 vs. price of NT$65.20 (19.4% below fair value)
  • GF Score™: 65/100

No single metric tells the full story. See the ROCO:4147 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


TaiMed Biologics Business Description

Address No. 607, Ruiguang Road, 3rd Floor, Neihu District, Taipei, TWN, 11492
TaiMed Biologics Inc is a biotechnology company engaged in developing, manufacturing, and commercializing new drugs for the treatment and prevention of infectious diseases. Its products include Trogarzo IV Infusion, Trogarzo IV Push, TMB-365, TMB-365/TMB-380 combination, and Antibody-Drug Conjugates (ADCs). The Group operates in the Americas, which generates maximum revenue, as well as Europe and Taiwan.
65GF Score

Get the complete analysis for ROCO:4147

GF Value Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$65.20
Price
NT$80.94
GF Value